Reported about 15 hours ago
A new study has reportedly linked Novo Nordisk's weight-loss drug Ozempic to a rare type of vision loss known as non-arteritic anterior ischemic optic neuropathy (NAION). The findings, which are yet to undergo peer review, align with earlier results from a Harvard University study published in July. Market experts discuss these implications and the company's stock performance year-to-date.
Source: YAHOO